sponsored
PatientsVille.com Logo

PatientsVille

Irritability Medical Research Studies

Up-to-date List of Irritability Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Irritability Medical Research Studies

Rank Status Study
1 Recruiting Effectiveness of Gabapentin on Chronic Irritability in Neurologically Impaired Children
Conditions: Neurologically Impaired;   Irritable Mood;   Signs and Symptoms, Digestive;   Sleeplessness;   Chronic Pain
Interventions: Drug: Gabapentin;   Drug: placebo
Outcome Measures: Symptom relief for chronic Irritability in neurologically impaired children using gabapentin.;   Prevalence of associated gastrointestinal and sleep problems in neurologically impaired children and improvement using gabapentin.
2 Recruiting Cognitive-Behavioral Therapy for Irritability in Adolescents With High Functioning Autism Spectrum Disorder
Conditions: Autism;   Autism Spectrum Disorder (ASD;   Asperger's Disorder;   Pervasive Developmental Disorder (PDD-NOS)
Intervention: Behavioral: Cognitive-Behavioral Therapy (CBT) for Irritability
Outcome Measure: ABC Irritability Scale
3 Recruiting Buspirone for the Treatment of Traumatic Brain Injury (TBI) Irritability and Aggression
Condition: Traumatic Brain Injury
Interventions: Drug: Buspirone;   Drug: Placebo
Outcome Measures: Neuropsychiatric Inventory-Irritability Domain;   Neuropsychiatric Inventory-Aggression Domain;   Neuropsychiatric Inventory-Distress Irritability Domain;   Neuropsychiatric Inventory-Distress Aggression Domain;   St. Andrews-Swansea Neurobehavioural Outcome Scale;   Personal Health Questionnaire;   Traumatic Brain Injury-Quality of Life Anger;   Global Impressions of Change;   Clinical Global Impressions;   Aggression and Irritability Impact Measure;   Generalized Anxiety Disorder
4 Unknown  The Effects of Soy Dietary Fiber in Adults With Diarrhea Predominant Irritable Bowel Syndrome
Condition: Diarrhea Predominant Irritable Bowel Syndrome
Interventions: Dietary Supplement: Soy Dietary Fiber;   Dietary Supplement: Rice powder
Outcome Measures: sum of irritable bowel syndrome symptom score;   irritable bowel syndrome symptom score;   Stool frequency and form;   Symptom control of irritable bowel syndrome;   Improvement of overall symptom in patient with irritable bowel syndrome;   Severity of overall symptom in patient with irritable bowel syndrome;   Severity of diarrhea;   Assessment for quality of life related with irritable bowel syndrome;   Assessment for patient satisfaction after administration completion
5 Recruiting The Effects of Multi-strain Probiotics in Adults With Diarrhea Predominant Irritable Bowel Syndrome
Condition: Diarrhea Predominant Irritable Bowel Syndrome
Interventions: Drug: Multi-strain probiotics;   Drug: Placebo powder
Outcome Measures: change of Irritable bowel syndrome symptom severity score (IBS-SSS);   Stool frequency and form;   Symptom control of irritable bowel syndrome;   Improvement of overall symptom in patient with irritable bowel syndrome;   Assessment for quality of life related with irritable bowel syndrome;   Assessment for patient satisfaction after administration completion
6 Unknown  Assessment of Small Intestinal Bowel Epithelial Gaps in Irritable Bowel Syndrome
Conditions: Irritable Bowel Syndrome;   Inflammatory Bowel Disease
Intervention:
Outcome Measure:
7 Unknown  Iyengar Yoga for Young People With Irritable Bowel Syndrome
Condition: Irritable Bowel Syndrome
Intervention: Behavioral: Iyengar yoga
Outcome Measures: Irritable bowel symptoms;   Quality of Life
8 Recruiting A Placebo-Controlled Trial of Pregabalin (Lyrica) for Irritable Bowel Syndrome
Condition: Irritable Bowel Syndrome
Interventions: Drug: Pregabalin (Lyrica);   Drug: Placebo
Outcome Measures: Primary aim: Collect preliminary data comparing effects of Pregabalin and placebo on abdominal pain/discomfort on bowel symptom score (BSS), overall BSS score, and adequate relief of irritable bowel syndrome (IBS) symptoms in patients with IBS;   To compare the effect of Pregabalin and placebo on self-reported overall and individual BSS scores;   compare effect of Pregabalin and placebo on adequate relief of IBS pain or discomfort at least 50% of the time;   To compare effect of Pregabalin and placebo on overall and individual BSS scores;   To compare the effect of Pregabalin and placebo on the proportion of patients with at least 3 point changes in 11 point pain and IBS scores
9 Recruiting Subsensory Sacral Nerve Stimulation for Irritable Bowel Syndrome
Condition: Irritable Bowel Syndrome
Interventions: Device: subsensory;   Device: External pacemaker, OFF;   Drug: Suprasensory
Outcome Measures: The Gastrointestinal Symptom Rating Scale - Irritable Bowel Syndrome version questionnaire;   Irritable Bowel Syndrome - Impact Scale questionnaire
10 Recruiting Open Trial of Duloxetine in Outpatients With Irritable Bowel Syndrome Symptoms and Co-Morbid Major Depression
Conditions: Major Depression;   Irritable Bowel Syndrome Symptoms
Intervention: Drug: Duloxetine
Outcome Measures: Montgomery-Asberg Depression Rating Scale (MADRS);   Gastrointestinal Symptoms Rating Scale (GSRS);   Clinician-Rated Global Impression Scales;   Visual Analogue Scales (VAS);   Somatization module of the Patient's Health Questionnaire (PHQ-15)
11 Recruiting Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Conditions: Major Depressive Disorder;   Irritability
Intervention: Drug: Brexpiprazole
Outcome Measures: Change from baseline to Week 6 in KSQ total score;   Change from baseline to Week 6 in KSQ anger-hostility subscore;   Change from baseline to Week 6 in BIS-11 total score;   Change from baseline to Week 6 in AAQ score;   Change from baseline to Week 6 in SIS total score;   Change from baseline to Week 6 in delay discounting - MCQ scores;   Change from baseline to Week 6 in delay discounting - EDT scores;   Change from baseline to Week 6 in IDS-C30 total score;   Change from baseline to Week 6 in MADRS total score;   Change from baseline to Week 6 in MADRS total score in patients with a pre-defined baseline BIS-11 total score;   Change from baseline to Week 6 in CPFQ total score;   Change from baseline to Week 6 in KSQ depression subscore;   Change from baseline to Week 6 in CGI-S score;   Change from baseline to Week 6 in CGI-S score in patients with a pre-defined baseline BIS-11 total score;   CGI-I score at Week 6;   CGI-I score at Week 6 in patients with a pre-defined baseline BIS-11 total score;   Change from Week 6 to Week 10 in KSQ anger-hostility subscore;   Change from Week 6 to Week 10 in BIS-11 total score;   Change from Week 6 to Week 10 in SIS total score;   Change from Week 6 to Week 10 in CGI-S score;   Change from Week 6 to Week 10 in delay discounting - MCQ scores;   Safety;   Tolerability;   Risk of suicidality
12 Unknown  Saccharomyces Boulardii in Diarrhea Dominant Irritable Bowel Syndrome
Condition: Irritable Bowel Syndrome
Interventions: Drug: Saccharomyces boulardii;   Drug: Methyl cellulose powder (low viscosity)
Outcome Measures: Any Improvement in symptoms of number of bowel habits, urgency, straining,sense of incomplete evacuation, stool form (evaluated by Bristol stool form scale, abdominal pain and bloating/flatulence;   Improvement in quality of life in diarrhea dominant IBS by validated IBS-QOL questionnaire.
13 Recruiting 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Condition: Irritable Bowel Syndrome With Diarrhea
Interventions: Drug: Ibodutant 10 mg;   Drug: Placebo
Outcome Measures: Weekly response for abdominal pain intensity AND stool consistency over 12 weeks of treatment in at least 50% of the weeks of treatment (6 out of 12 weeks).;   Weekly response for abdominal pain intensity over 12 weeks of treatment in at least 50% of the weeks of treatment (6 out of 12 weeks).;   Weekly response for stool consistency over 12 weeks of treatment in at least 50% of the weeks of treatment (6 out of 12 weeks).;   Weekly Response for relief of overall IBS signs and symptoms over 12 weeks of treatment in at least 50% of the weeks of treatment (6 out of 12 weeks).;   Evaluation of rebound effects
14 Recruiting 52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Condition: Irritable Bowel Syndrome With Diarrhea
Interventions: Drug: Ibodutant 10 mg;   Drug: Placebo
Outcome Measures: Weekly response for abdominal pain intensity AND stool consistency over the first 24 weeks of treatment in at least 50% of the weeks of treatment (12 out of 24 weeks).;   Weekly response for abdominal pain intensity over the first 24 weeks of treatment in at least 50% of the weeks of treatment (12 out of 24 weeks).;   Weekly response for stool consistency over the first 24 weeks of treatment in at least 50% of the weeks of treatment (12 out of 24 weeks).;   Weekly response for relief of overall IBS signs and symptoms over the first 24 weeks of treatment in at least 50% of the weeks (12 out of 24);   Sustained efficacy
15 Recruiting Study to Investigate the Irritation Potential of GSK1940029 Gel
Condition: Acne Vulgaris
Interventions: Drug: 0.3% GSK1940029 gel;   Drug: 1% GSK1940029 gel;   Drug: 0.3%/1% vehicle gel only;   Other: Sterile distilled water;   Other: 0.5% SLS in sterile distilled water;   Other: 0.1% SLS in sterile distilled water;   Other: Patch only
Outcome Measures: Primary cutaneous irritation scores;   Cumulative cutaneous irritation scores;   Facial irritation scores;   Lanman-Maibach irritation classifications;   Tolerability of GSK1940029 as assessed by Clinical monitoring/observation;   Tolerability of GSK1940029 as assessed by adverse events (AEs);   Safety and tolerability of GSK1940029 as assessed by clinical laboratory tests;   Safety and tolerability of GSK1940029 as assessed by vital signs measurements;   Safety and tolerability of GSK1940029 as assessed by clinical monitoring/observation;   Ocular tolerability of topical applications of GSK1940029;   Plasma GSK1940029 pharmacokinetics (PK)
16 Unknown  Irritable Bowel Syndrome and Lactibiane Tolerance
Condition: Irritable Bowel Syndrome
Interventions: Dietary Supplement: Lactibiane Tolerance;   Dietary Supplement: Placebo
Outcome Measures: Severity of bowel symptoms according to the Francis Score;   Quality of life;   Severity of Anxiety/Depression;   Impact of the complementation on fatigue;   Impact of the intervention on immunological parameters in stools;   Impact of the intervention on immunological parameters in blood;   severity of the anxiety/depression
17 Recruiting Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders
Condition: Autism Spectrum Disorders
Interventions: Drug: Riluzole;   Drug: placebo
Outcome Measures: Clinical Global Impression-Improvement;   Aberrant Behavior Checklist- Irritability
18 Recruiting Delivered Dietary Intervention for Children With Irritable Bowel Syndrome
Conditions: Irritable Bowel Syndrome;   Abdominal Pain
Interventions: Other: Low fermentable substrate diet;   Other: High fermentable substrate diet
Outcome Measures: Average daily abdominal pain frequency;   Abdominal pain severity;   Hydrogen gas production
19 Unknown  Efficacy of Hair Transplantation Compared With Hypodermic Needle Irritation in Alopecia Areata
Conditions: Alopecia Areata;   Alopecia;   Balding
Interventions: Procedure: Hair transplantation;   Procedure: Hypodermic needle irritation
Outcome Measure: Change in follicular growth
20 Recruiting Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome
Condition: Irritable Bowel Syndrome (IBS)
Intervention: Other: Fecal transplantation
Outcome Measures: Effect of fecal microbiota transplantation on the symptoms of IBS patients using the IBS version of the gastrointestinal symptom rating scale (GSRS-IBS);   Effect of fecal transplantation on IBS patients' visceral perception (Pain scores on the visual analogue scale during barostat procedure);   Effect of fecal transplantation on IBS patients' composition of mucosal microbiota (HITChip analysis);   Effect of fecal transplantation on IBS patients' composition of fecal microbiota (HITChip analysis);   Effect of fecal transplantation on IBS patients' mucosal immune cell composition (lymphocyte fingerprinting using flow cytometry);   Effect of fecal microbiota transplantation on the symptoms of IBS patients using the IBS - severity scoring system (IBS-SSS);   Effect of fecal microbiota transplantation on the symptoms of IBS patients using the health-related quality of life questionnaire for IBS patients (IBS-QOL);   Effect of fecal microbiota transplantation on the symptoms of IBS patients using the hospital and anxiety depression scale (HADS);   Effect of fecal microbiota transplantation on the general health of IBS patients using the SF-36 survey

These studies may lead to new treatments and are adding insight into Irritability etiology and treatment.

A major focus of Irritability research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Irritability